ZOGENIX INC (ZGNX)

Common Stock

26.68  +0.42 (+1.6%)

After market: 26.69 +0.01 (+0.04%)

Fundamental Rating

2

Overall ZGNX gets a fundamental rating of 2 out of 10. We evaluated ZGNX against 198 industry peers in the Pharmaceuticals industry. ZGNX may be in some trouble as it scores bad on both profitability and health. ZGNX is valued quite expensively, but it does show have an excellent growth rating.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

ZGNX had negative earnings in the past year.
In the past 5 years ZGNX always reported negative net income.
In the past 5 years ZGNX always reported negative operating cash flow.

1.2 Ratios

Industry RankSector Rank
ROA -48.54%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -274.33%
PM (TTM) -278.4%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for ZGNX has been increased compared to 1 year ago.
ZGNX has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -2.21, we must say that ZGNX is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 0.88 indicates that ZGNX is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF N/A
Altman-Z -2.21
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ZGNX has a Current Ratio of 3.63. This indicates that ZGNX is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 3.57 indicates that ZGNX has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 3.63
Quick Ratio 3.57

More info and screens

7

3. Growth

3.1 Past

The earnings per share for ZGNX have decreased by -5.99% in the last year.
ZGNX shows a strong growth in Revenue. In the last year, the Revenue has grown by 498.88%.
Measured over the past years, ZGNX shows a very strong growth in Revenue. The Revenue has been growing by 23.14% on average per year.
EPS 1Y (TTM)-5.99%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q22.22%
Revenue 1Y (TTM)498.88%
Revenue growth 3Y11.58%
Revenue growth 5Y23.14%
Revenue growth Q2Q213.04%

3.2 Future

The Earnings Per Share is expected to grow by 12.86% on average over the next years. This is quite good.
ZGNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 103.02% yearly.
EPS Next Y26.75%
EPS Next 2Y35.4%
EPS Next 3Y20.54%
EPS Next 5Y12.86%
Revenue Next Year113.18%
Revenue Next 2Y103.93%
Revenue Next 3Y102.65%
Revenue Next 5Y103.02%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ZGNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ZGNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -6.29

4.3 Compensation for Growth

A more expensive valuation may be justified as ZGNX's earnings are expected to grow with 20.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.4%
EPS Next 3Y20.54%

More info and screens

0

5. Dividend

5.1 Amount

ZGNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZOGENIX INC

NASDAQ:ZGNX (3/4/2022, 7:10:11 PM)

After market: 26.69 +0.01 (+0.04%)

26.68

+0.42 (+1.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.49B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.54%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -274.33%
PM (TTM) -278.4%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.63
Quick Ratio 3.57
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-5.99%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y26.75%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)498.88%
Revenue growth 3Y11.58%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y